Literature DB >> 23635999

Effect of angiotensin converting enzyme gene I/D polymorphism and its expression on clinical outcome in acute respiratory distress syndrome.

A E Tsantes1, P Kopterides, S Bonovas, P Bagos, G Antonakos, G K Nikolopoulos, A Gialeraki, V Kapsimali, E Kyriakou, S Kokori, K Dima, A Armaganidis, I Tsangaris.   

Abstract

BACKGROUND: The role of the D allele of the angiotensin-converting enzyme (ACE) gene I/D polymorphism in the clinical outcomes of patients with acute lung injury and acute respiratory distress syndrome (ALI/ARDS) remains controversial. Our aim was to assess simultaneously the effect of the ACE I/D polymorphisms as well as the serum and BALF ACE levels on prognosis of patients with ARDS.
METHODS: Sixty-nine mechanically ventilated patients with ALI/ARDS were recruited. ACE activity levels both in serum and BALF were assessed by chemical methods. Patients were genotyped for ACE I/D polymorphisms. Time-to-event analysis evaluated the variables associated with the 28-day and 90-day mortality. Finally, we performed a meta-analysis of studies examining the association between ACE I/D polymorphisms and mortality of ALI/ARDS patients.
RESULTS: In the multivariable model, age, lung compliance, serum lactate and serum ACE levels were significantly associated with both 28- and 90-day mortality. No significant correlation was found between serum and BALF ACE levels (Spearman's rho=0.054; P=0.66). Serum ACE concentrations were significantly higher (P=0.046) in patients with D/D genotype versus the two other groups combined (I/D and I/I genotypes). The meta-analysis of 6 studies (including ours) provided evidence that D allele is significantly associated with increased mortality in ALI/ARDS patients, yielding a per-allele odds ratio of 1.76 (95% CI: 1.19, 2.59).
CONCLUSION: Serum ACE levels appear to be affected by the I/D polymorphism and are correlated with prognosis in patients with ALI/ARDS indicating that further investigation of the clinical significance of the ACE in ARDS might be of value.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23635999

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  14 in total

1.  Genetic susceptibility to nosocomial pneumonia, acute respiratory distress syndrome and poor outcome in patients at risk of critical illness.

Authors:  Lyubov E Salnikova; Tamara V Smelaya; Irina N Vesnina; Arkadiy M Golubev; Viktor V Moroz
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

2.  Analysis of the Pattern, Alliance and Risk of rs1799752 (ACE I/D Polymorphism) with Essential Hypertension.

Authors:  Digishaben D Patel; Deepak N Parchwani; Nirupama Dikshit; Tanishk Parchwani
Journal:  Indian J Clin Biochem       Date:  2020-10-31

Review 3.  The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19.

Authors:  Iphigenia Gintoni; Maria Adamopoulou; Christos Yapijakis
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

4.  Daily sodium intake influences the relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism and hypertension in older adults.

Authors:  Ivna V Freire; Cezar A Casotti; Ícaro J S Ribeiro; Jonas R D Silva; Ana A L Barbosa; Rafael Pereira
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-09       Impact factor: 3.738

5.  The evolving role of the renin-angiotensin system in ARDS.

Authors:  Eleni Vrigkou; Iraklis Tsangaris; Stefanos Bonovas; Argyrios Tsantes; Petros Kopterides
Journal:  Crit Care       Date:  2017-12-28       Impact factor: 9.097

6.  A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.

Authors:  Akram Khan; Cody Benthin; Brian Zeno; Timothy E Albertson; John Boyd; Jason D Christie; Richard Hall; Germain Poirier; Juan J Ronco; Mark Tidswell; Kelly Hardes; William M Powley; Tracey J Wright; Sarah K Siederer; David A Fairman; David A Lipson; Andrew I Bayliffe; Aili L Lazaar
Journal:  Crit Care       Date:  2017-09-07       Impact factor: 9.097

7.  COVID-19 and hypertension.

Authors:  Spoorthy Kulkarni; Bernadette L Jenner; Ian Wilkinson
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Apr-Jun       Impact factor: 1.636

8.  Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers.

Authors:  Rangaprasad Sarangarajan; Robert Winn; Michael A Kiebish; Chas Bountra; Elder Granger; Niven R Narain
Journal:  J Racial Ethn Health Disparities       Date:  2020-09-08

9.  Biomarkers and Gene Polymorphisms in Members of Long- and Short-lived Families: A Longevity Study.

Authors:  Vana Kolovou; Olga Diakoumakou; Athanasia K Papazafiropoulou; Niki Katsiki; Elisabeth Fragopoulou; Ioannis Vasiliadis; Dimitris Degiannis; Leonidas Duntas; Smaragdi Antonopoulou; Genovefa Kolovou
Journal:  Open Cardiovasc Med J       Date:  2018-07-31

10.  Associations of ACE gene insertion/deletion polymorphism, ACE activity, and ACE mRNA expression with hypertension in a Chinese population.

Authors:  Qingfang He; Chunhong Fan; Min Yu; Gina Wallar; Zuo-Feng Zhang; Lixin Wang; Xinwei Zhang; Ruying Hu
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.